Navigation Links
Turning green gunk to gold, anti-cancer gold

Combining synthetic chemistry techniques with a knowledge of the properties and actions of enzymes, scientists have been able to produce an exciting class of anti-cancer drugs originally isolated from blue-green algae.

This accomplishment is expected to make it possible to produce enough of the promising drugs for use in clinical trials.

In a study featured on the cover of the January issue of the journal ACS Chemical Biology, a scientific team lead by University of Michigan Life Sciences Institute Research Professor David H. Sherman and researcher Zachary Q. Beck found the trick to turning the green gunk into gold---cancer fighting gold.

"It was simply too difficult to use the native blue-green algae for high-level production using traditional fermentation approaches," said Sherman. But the compound, called cryptophycin 1, held so much promise as an anti-cancer drug that organic chemists got busy trying to find ways to make a synthetic form of the compound in large enough quantities for clinical trials.

Developing an efficient synthetic route to natural product compounds and their analogs is often an essential step in drug development. With drugs such as penicillin and tetracycline, it can easily be done, but cryptophycins present more of a challenge. Sherman's team realized that with all cryptophycins, the most difficult step came very late in the synthesis, at the point at which a key part called an epoxide---a highly strained, three-membered ring oxygen-containing group, crucial for the drug's anti-cancer activity---becomes attached to the molecule.

The epoxide group can be attached in two configurations, designated as alpha and beta. Scientists have known for several years that the beta configuration was absolutely required for the anti-cancer properties of the drug, but were unable to devise efficient synthetic strategies that favored that configuration.

Sherman's team accomplished this by isolating
'"/>

Source:University of Michigan


Page: 1 2

Related biology news :

1. Turning viruses into allies against cancer
2. Turning a cellular sentinel into a cancer killer
3. New research indicates a troubled greenhouse is brewing
4. Genetic defects give the immune system the green light to attack the pancreas
5. While on trail of dioxin, scientists pinpoint cancer target of green tea
6. UN successfully tests green pesticide against locusts
7. Bacteria are key to green plastics, drugs
8. New tools used to control foodborne hepatitis A outbreaks related to green onions
9. Asleep in the deep: Model helps assess ocean-injection strategy for combating greenhouse effect
10. Predators keep the world green, ecologists find
11. Amazon rainforest greens up in the dry season

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Turning green gunk gold anti cancer gold

(Date:11/19/2009)...ain chemical with an unwieldy name: 4-hydroxybutyr...ed as a date-rape drug. , Now, a team of Ohio a...by which 4-HB is metabolized by the body. "This is...ibson, professor and chair of biological sciences ...of the research team. "It may provide new clues o...
(Date:11/19/2009)...s are revealing the genetic instructions inside co...ize, has one of the most complex sequences of DNA ...n genomicist David Schwartz, who was one of more t...ence . , "The maize genome is a true maze full ...led would-be sequencers for years," says Schwartz....
(Date:11/19/2009)...four-year, multi-institutional effort co-led by th...s culminated today in publication of a landmark se...in unprecedented detail the DNA sequence of maize ...lled by North American consumers, is one of the wo...agricultural crop grown in the United States, repr...
Breaking Biology News(10 mins):Researchers begin to decipher metabolism of sexual assault drug 2Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4Caraco Pharmaceutical Laboratories Ltd Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations 5070 1Caraco Pharmaceutical Laboratories Ltd Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations 5070 2Lupin Expands Branded Play 5066 1Lupin Expands Branded Play 5066 2Lupin Expands Branded Play 5066 3Despite size NFL players not more likely to develop heart disease even after retirement 58486 1Despite size NFL players not more likely to develop heart disease even after retirement 58486 2
...is release is available in French . , ,Saskatoo...y is good for you. But why exactly is it good for ...nd tissues of the body? What do we need to know so...y to combat chronic diseases such as arthritis, di...hological factors prevent people from exercising o...
...entary school students will eat more whole grains ...uced into their school lunches, a new University o... strongly recommended as part of a healthy diet, b...or this study, researchers from the university,s d...how much bread students threw away, and whether th...
... the Tour de France to NASCAR, competitors and fan...rategy -- and the ability to use elements like aer... closely behind a leader than to be out in front -... happens in reverse: It,s the leader of a pack who...ounter more resistance -- and have to expend more ...
Other Biology News:Physical activity and health: Finding the right prescription 2Following the leader can be a drag, according to student's research on flapping flags 2
(Date:11/19/2009)...PRNewswire/ - Aegera Therapeutics Inc. announced t...ed Phase 2B study of AEG35156, a targeted antisens...e oncology indications. ,, The study, entitled ...inked Inhibitor of Apoptosis (XIAP) Antisense AEG3...e and Idarubicin in AML Following Failure of a Sin...
(Date:11/19/2009)...tria, November 19 AFFiRiS AG will ...ct candidate at an unexpectedly early,stage of dev... enter into,Phase II clinical trial early in 2010....the completion of two Phase I trials with the cand...ecision on the first interim,analysis of the secon...
(Date:11/18/2009)... polka-dotted postage stamp that can sniff out poi...olors. , As reported in the Sept. 13 issue of th...his team at the University of Illinois have develo...f toxic industrial chemicals (TICs) that is simple...dors. This sensor array could be useful in detect...
(Date:11/18/2009).... 18 Masimo (Nasdaq: ...Measure-Through Motion and Low-Perfusion pulse oxi....H.A., one of the largest healthcare Group Purchas...lti-year purchasing agreement for "gold standard" ... offers preferred contract pricing to Uni.H.A.,s 5...
Breaking Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4
...23 Boston Scientific,Corporation (NYSE: BSX ) to... $2 billion revolving line of credit and $5 billio...onal financial flexibility as it implements,initia... were pleased to work with our lenders to amend ou...Chief Executive Officer of Boston,Scientific. "The...
...23 Mirus Bio Corporation today,announced that it ... since,January of this year totaling $5.4 million....ng $2.4 million to further develop the Company...orm and alternative nanoparticle technologies,...ver applications; [Principal Investigat...
...Aug. 23 AspenBio Pharma,Inc. (OTC Bulletin Board:...cated to the development of novel drugs and diagno...application to list its common stock on the,NASDAQ... The company anticipates its shares of common sto...with the open of trading on Tuesday, August 28,200...
Other Biology Technology:Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan 2Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan 3Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan 4Mirus Bio Awarded Grants & Contracts of Over $5 Million 2AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol 'APPY' 2AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol 'APPY' 3AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol 'APPY' 4
...- 5 units/µL ,• High specific activit...ll; Leaves an 'A' overhang ,• Processes ...ry high activity in primer extension and other mol... of the enzyme, each lot has been functionally tes...
AmpliTaq DNA Polymerase with Buffer II from Applied Biosystems
...- 5 units/µL ,• High specific activit...ll; Leaves an 'A' overhang ,• Processes ,...y high activity in primer extension and other mole...of the enzyme, each lot has been functionally test...
AmpliTaq DNA Polymerase with Buffer I from Applied Biosystems
Biology Products: